New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Scientists have conducted a pioneering study on the benefits of intermittent fasting. Not eating anything from 5 p.m. until 9 a.m. the following day (early fasting) helps to a greater extent to ...

Researchers at UT Southwestern Medical Center discovered that genetically modifying fat cells in obese mice to produce higher ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...